Vor Biopharma Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Vor Biopharma Inc. (VOR) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $2.32 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2023-08-10
- 2023-06-30: Operating Lease, Right-of-Use Asset, Amortization Expense 6 month $2.32M.
- 2022-06-30: Operating Lease, Right-of-Use Asset, Amortization Expense 6 month $1.31M.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month |
|---|---|
| 2023-06-30 | $2.32M 10-Q · filed 2023-08-10 |
| 2022-06-30 | $1.31M 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |